Table I.
Clinical characteristics of patients with PCNSL.
| Characteristics | Patients |
|---|---|
| Median age (range) | 56 (11–85) |
| Age, n (%), years | |
| >60 | 35/89 |
| ≤60 | 54/89 |
| Sex, n (%) | |
| Male | 53/89 (59.6) |
| Female | 36/89 (40.4) |
| ECOG, n (%) | |
| 0–1 | 21/89 (23.6) |
| 2–4 | 68/89 (76.4) |
| LDH, n (%) | |
| Elevated | 30/76 (39.5) |
| Normal | 46/76 (60.5) |
| No. of lesions, n (%) | |
| 1 | 29/89 (32.6) |
| ≥2 | 60/89 (67.4) |
| Deep brain lesions, n (%) | |
| Absent | 28/89 (31.5) |
| Present | 61/89 (68.5) |
| Chemotherapy, n (%) | |
| HD-MTX+Ara-C | 39/73 (53.4) |
| HD-MTX+TMZ | 34/73 (46.6) |
| Median OS (95% CI) | 45.3 (25.01–65.59) |
| Median PFS (95% CI) | 30.0 (13.43–46.57) |
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; HD-MTX + Ara-C, high-dose methotrexate + cytarabine; HD-MTX + TMZ, high-dose methotrexate + tomozolomide; OS, overall survival; PFS, progression-free survival; CI, confidence interval.